Title | Organization | Keywords | Activity Code | FOA | LOI Due Date | Application Due Date |
---|---|---|---|---|---|---|
Clinical-Community Linkages to Address Unmet Social Needs and Adverse Social Determinants of Health to Advance Health Equity among Populations Experiencing Health Disparities: The Bridge-to-Care Initiative (R01 Clinical Trial Optional) | National Institutes of Health | Health equity, social determinants of health, community-based interventions, health disparities, underserved populations, clinical trials (optional) | RFA-NR-24-003 | 2/21/2024 | 3/22/2024 | |
Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) | National Institutes of Health | health disparities, social determinants, intervention research, SDOH | RFA-NR-24-004 | 2/22/2024 | 3/22/2024 | |
NCMRR Early Career Research Award (R03 Clinical Trial Optional) | National Institutes of Health | Biomedical Informatics, Cancer Informatics, Health Data Management, Cancer Research | PAR-23-029 | 3/28/2024 | ||
(NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional) | National Institutes of Health | bioethics, NIH, research, capacity building | Admin Supp | NOT-OD-24-031 | 3/31/2024 | |
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | National Institutes of Health | Early-stage, innovation, ESI | PA-21-138 | 4/1/2024 | ||
(NOSI): Administrative Supplements to Enhance Institutional Data Science Capacity | National Institutes of Health | administrative supplements, data science, capacity, underserved communities, underrepresented students | Admin Supp | NOT-OD-23-123 | 4/1/2024 | |
NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) | National Institutes of Health | NHGRI technology development, coordinating center, clinical trials not allowed | RFA-HG-24-013 | 3/1/2024 | 4/2/2024 | |
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | National Institutes of Health | Cancer Control, Population Sciences, Clinical Trial | PAR-21-190 | 4/7/2024 | ||
(NOSI): Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows | National Institutes of Health | childcare costs, Ruth L. Kirschstein NRSA, individual fellows, administrative supplements | Admin Supp | NOT-OD-21-070 | 4/7/2024 | |
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) | National Institutes of Health | Early-stage, predoctoral, training, clinical, fellowship, physician | PA-23-260 | 4/8/2024 | ||
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) | National Institutes of Health | Early-stage, predoctoral, training, clinical, fellowship, physician | PA-23-272 | 4/8/2024 | ||
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity) | National Institutes of Health | Early-stage, predoctoral, training, clinical, fellowship, physician, Diversity, | PA-21-052 | 4/8/2024 | ||
Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) | National Institutes of Health | Diet, gut microbiome, obesity, weight, policy, | PAR-21-305 | 4/8/2024 | ||
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) | National Institutes of Health | Fellowship, Postdoctoral, early-stage, mentor, | PA-23-262 | 4/8/2024 | ||
(NOSI): Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship Awards to Support Training in Research Related to Down Syndrome as Part of the INCLUDE Project | National Institutes of Health | INCLUDE Project, Down Syndrome, Training, Research | F32,F30,F31 | NOT-OD-22-126 | 4/8/2024 | |
Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01) | National Institutes of Health | Population assessment, Tobacco and health, Biospecimen access | PAR-24-027 | 4/30/2024 | ||
Limited Competition: Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed) | National Institutes of Health | Mutant mice, resource centers, research, clinical trials not allowed | PAR-24-105 | 5/1/2024 | ||
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) | National Institutes of Health | Nanotechnology, Brain Disorders, Biomedical Systems, Biomarkers | PAR-23-246 | 5/3/2024 | ||
NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed) | National Institutes of Health | Health Equity Research, Cancer Disparities, Specifically named cancers (Various Cancer Types), Community Exposures | PAR-23-229 | 4/6/2024 | 5/6/2024 | |
(NOSI): Promoting Research on Interoception and Its Impact on Health and Disease | National Institutes of Health | Interoception, | R01,R21 | NOT-AT-21-002 | 5/6/2024 | |
(NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health | National Institutes of Health | systems science, child health, adolescent health, development, cancer, prevention, disparities | R01 | NOT-HD-20-032 | 5/7/2024 | |
(NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects | National Institutes of Health | Electronic Nicotine Delivery Systems (ENDS), Alternative Nicotine, Tobacco Delivery Systems, Health Effects | R21,R01,Admin Supp,R34,R03,R61/R33 | NOT-OD-22-023 | 5/8/2024 | |
Drug Development Tools Research Grants (U01) Clinical Trials Optional | National Institutes of Health | development, translational, clinical, | RFA-FD-24-030 | 5/13/2024 | ||
Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | National Institutes of Health | Biomedical Informatics, Cancer Informatics, Health Data Management, Cancer Research | PAR-22-071 | 5/17/2024 | ||
Strategies to Improve Health Outcomes and Advance Health Equity in Rural Populations (R01 Clinical Trial Optional) | National Institutes of Health | R01 | RFA-NR-24-005 | 4/17/2024 | 5/17/2024 | |
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional | National Institutes of Health | U01 | RFA-FD-24-037 | 5/20/2024 | ||
Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) | National Institutes of Health | Health Careers Opportunity Program, Cancer Symptom Management, Gene Editing, Cancer Survivorship, Training | PAR-23-069 | 5/25/2024 | ||
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) | National Institutes of Health | investigator-initiated trial, prevention, dectetion, organ system, translational, genetic, biochemical, | PAR-23-284 | 4/25/2024 | 5/25/2024 | |
Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | National Institutes of Health | Training, clinical, biomedical, innovation, | PAR-23-278 | 5/25/2024 | ||
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | National Institutes of Health | Training, clinical, biomedical, innovation, | PAR-23-277 | 5/25/2024 | ||
Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | National Institutes of Health | Training, clinical, biomedical, innovation, | PAR-23-276 | 5/25/2024 | ||
NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed) | National Institutes of Health | aging research, biomedical research, career development, diverse backgrounds, educational activities, health disparities, MSTEM fields, research experiences, underrepresented groups | PAR-24-135 | 4/25/2024 | 5/25/2024 | |
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required) | National Institutes of Health | early-stage investigators, basic research, human studies, innovative approaches, high-risk research | PAR-24-076 | 5/29/2024 | ||
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) | National Institutes of Health | early-stage investigators, basic research, clinical trials (not allowed), innovative approaches, high-risk research | PAR-24-075 | 5/29/2024 | ||
Translational Neural Devices (R61/R33 - Clinical Trial Optional) | National Institutes of Health | Translational Neural Devices, Clinical Trial Optional | PAR-24-151 | 3/30/2024 | 5/29/2024 | |
Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult Services (U01 Clinical Trials Optional) | National Institutes of Health | Regional genomic medicine, eConsult services, clinical trials (optional) | RFA-HG-24-001 | 4/30/2024 | 5/30/2024 | |
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial Optional) | National Institutes of Health | Building Interdisciplinary Research Careers, Women's Health, BIRCWH, K12 Clinical Trial Optional | RFA-OD-24-013 | 5/30/2024 | ||
Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) | National Institutes of Health | radiation biodosimetry, assays, triage, predicting health outcomes, acute injuries, delayed injuries, public health emergency | RFA-AI-24-003 | 4/30/2024 | 5/31/2024 | |
Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional | National Institutes of Health | ultra-rare cancers, therapeutic development, FDA | RFA-FD-24-019 | 2/25/2024 | 5/31/2024 | |
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | National Institutes of Health | Mechanisms, Cancer risk, Incretin mimetics, Clinical trial optional | PAR-23-279 | 5/6/2024 | 6/5/2024 | |
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | Animal models, Translational research, | PAR-23-281 | 6/5/2024 | ||
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | National Institutes of Health | Cancer Health Disparities, Cutting-Edge Technologies, Digital Pathomics, Investigator-Initiated Research | PAR-23-245 | 6/5/2024 | ||
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | National Institutes of Health | Nanotechnology, Brain Disorders, Biomedical Systems, Biomarkers | PAR-23-273 | 6/5/2024 | ||
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | National Institutes of Health | Nanotechnology, Brain Disorders, Biomedical Systems, Biomarkers | PAR-23-254 | 6/5/2024 | ||
Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required) | National Institutes of Health | SBIRT/P, Health Disparities, Clinical Trial, Adult Populations | PAR-23-270 | 6/5/2024 | ||
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | National Institutes of Health | Investigator-Initiated Research, surgery, | PAR-21-331 | 5/6/2024 | 6/5/2024 | |
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | National Institutes of Health | Cancer Genetics, Disparitites, biology, cancer prevenetion, novel strategies, basic research, | PAR-21-322 | 6/5/2024 | ||
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | National Institutes of Health | microbiome, immune response, novel molecules, | PAR-22-061 | 6/5/2024 | ||
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | National Institutes of Health | regenerative medicine, biomimetic, tissue engineering, biology, novel models, innovation | PAR-22-099 | 5/6/2024 | 6/5/2024 | |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | National Institutes of Health | Microbiome, imaging, therapy, immune response, preclinical, bacteria, | PAR-22-085 | 6/5/2024 | ||
Biology of Bladder Cancer (R01 Clinical Trial Optional) | National Institutes of Health | biology, genetics, novel interventions, | PAR-22-218 | 5/6/2024 | 6/5/2024 | |
The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) | National Institutes of Health | Innovation, population research, occupation, work-place, disparities, diversity, social | PAR-21-275 | 6/5/2024 | ||
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | National Institutes of Health | collaborative, therapies, basic, translational, clinical, biomarkers, | PAR-21-329 | 5/6/2024 | 6/5/2024 | |
Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional) | National Institutes of Health | Innovation, patient-clinician, communication, disparities, diversity, outcomes, equity | PAR-22-064 | 6/5/2024 | ||
Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | National Institutes of Health | Survivor, treatment, diversity, observational | PAR-23-292 | 5/6/2024 | 6/5/2024 | |
Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed) | National Institutes of Health | education, skills development, biomedical, development, predoctoral, postdoctoral | RFA-HL-25-001 | 5/6/2024 | 6/5/2024 | |
Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | National Institutes of Health | cancer imaging, inflammation, molecular imaging, PET, MRI, biomarkers, diagnosis, prognosis | PAR-21-294 | 5/6/2024 | 6/5/2024 | |
Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional) | National Institutes of Health | Health disparities, sexual and gender minorities (SGM), mental health, substance use, access to care, social determinants of health | PAR-24-077 | 6/5/2024 | ||
Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) | National Institutes of Health | neuroscience, chemical probes, in vivo studies, drug discovery, neurotransmitters, brain imaging | PAR-24-088 | 6/5/2024 | ||
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | National Institutes of Health | clinical trials, early phase, treatment, diagnosis, innovative therapies | PAR-24-085 | 1/5/2024 | 6/5/2024 | |
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | National Institutes of Health | cancer prevention, clinical trials, intervention, lifestyle factors, environmental exposures | PAR-24-072 | 5/6/2024 | 6/5/2024 | |
International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed? | National Institutes of Health | global health, career development, collaborative research | PAR-24-113 | 5/5/2024 | 6/5/2024 | |
AHRQ Health Services Research Projects (R01) | National Institutes of Health | equity, health services | PA-24-154 | 6/5/2024 | ||
Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional) | National Institutes of Health | health disparities, long-term effects, disasters, healthcare systems, populations | PAR-24-109 | 5/6/2024 | 6/5/2024 | |
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) | National Institutes of Health | Clinical, biology, biomarker, clinical | PAR-22-049 | 5/8/2024 | 6/7/2024 | |
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) | National Institutes of Health | Exploratory, Early-stage, cancer control, novel, ESI | PAR-21-341 | 5/8/2024 | 6/7/2024 | |
(NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health | National Institutes of Health | patient adherence, treatment adherence, prevention adherence, health outcomes, | R01,R21,R03,R41/R42,R43/R44,R21/R33,UG3/UH3,R34 | NOT-OD-21-100 | 6/7/2024 | |
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) | National Institutes of Health | Diversity, Research Scientist Development, Clinical Trial | PAR-21-295 | 6/12/2024 | ||
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required) | National Institutes of Health | Diversity, Research Scientist Development, Clinical Trial, ESI | PAR-21-299 | 6/12/2024 | ||
NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed) | National Institutes of Health | Diversity, Early-stage, training, career transition, postdoctoral, biomedical, ESI | PAR-21-301 | 6/12/2024 | ||
NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required) | National Institutes of Health | Clinical Trials, Diversity, Early-stage, Career Transition, postdoctoral, ESI | PAR-21-302 | 6/12/2024 | ||
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | National Institutes of Health | Clinical Trials, Early-stage, diagnosis, precention, disparities, molecules, xenograft, biology, ESI | PAR-22-216 | 6/12/2024 | ||
The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional) | National Institutes of Health | cancer research, tenure-track faculty position, mentored research training, career development, clinical trials | PAR-24-117 | 6/12/2024 | ||
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | National Institutes of Health | early-stage, postdoctoral, cancer control, cancer prevention, data science | PAR-23-286 | 6/14/2024 | ||
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | National Institutes of Health | early-stage, postdoctoral, cancer control, cancer prevention, data science | PAR-23-287 | 6/14/2024 | ||
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) | National Institutes of Health | early-stage, postdoctoral, cancer control, cancer prevention, data science | PAR-23-288 | 6/14/2024 | ||
BRAIN Initiative: Scaled reagent resources for brain cell type-specific access across vertebrate species (U01 Clinical Trial Not Allowed) | National Institutes of Health | Scaled Reagent Resources, Brain Cell Type-Specific Access, Vertebrate Species, U01 Clinical Trial Not Allowed | RFA-MH-25-100 | 5/15/2024 | 6/14/2024 | |
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | National Institutes of Health | Mechanisms, Incretin mimetics, Clinical trial not allowed | PAR-23-280 | 5/17/2024 | 6/16/2024 | |
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | National Institutes of Health | Health Equity Research, Cancer Disparities, Specifically named cancers (Various Cancer Types), Community Exposures | PAR-23-255 | 6/16/2024 | ||
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | National Institutes of Health | Investigator-Initiated Research, surgery, early-stage | PAR-21-332 | 5/17/2024 | 6/16/2024 | |
Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed) | National Institutes of Health | Cancer Genetics, Disparitites, biology, cancer prevenetion, novel strategies, basic research, | PAR-21-324 | 6/16/2024 | ||
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | National Institutes of Health | Cancer Genetics, Disparitites, biology, cancer prevenetion, novel strategies, basic research, | PAR-21-323 | 6/16/2024 | ||
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | National Institutes of Health | microbiome, immune response, novel molecules, early-stage | PAR-22-062 | 6/16/2024 | ||
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | National Institutes of Health | Microbiome, imaging, therapy, immune response, preclinical, bacteria, exploratory | PAR-22-086 | 6/16/2024 | ||
Biology of Bladder Cancer (R21 Clinical Trial Optional) | National Institutes of Health | Exploratory, biology, genetics, novel interventions, | PAR-22-219 | 5/17/2024 | 6/16/2024 | |
Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) | National Institutes of Health | immunity, immunological memory, immune system | PAR-24-112 | 5/17/2024 | 6/16/2024 | |
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | National Institutes of Health | early- career, training, basic | PAR-24-039 | 6/18/2024 | ||
Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required) | National Institutes of Health | U34 | RFA-AA-24-006 | 5/19/2024 | 6/18/2024 | |
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) | National Institutes of Health | Systems-level, mechanisms of responses. Therapy, novel, data, | PAR-22-234 | 5/21/2024 | 6/20/2024 | |
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) | National Institutes of Health | mind-body interventions, clinical trials, feasibility studies, multi-site research, chronic pain, stress management | PAR-24-083 | 6/20/2024 | ||
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) | National Institutes of Health | mind-body interventions, clinical trials, feasibility studies, | PAR-24-084 | 6/20/2024 | ||
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) | National Institutes of Health | Complementary and integrative health, remote interventions, mHealth, clinical trials (required) | PAR-24-086 | 5/21/2024 | 6/20/2024 | |
(NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | National Institutes of Health | medical devices, chronic pain, opioid use disorder, NIH HEAL Initiative | U44,UG3/UH3 | NOT-NS-23-002 | 6/20/2024 | |
Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required) | National Institutes of Health | clinical, multi-site, data, center | PAR-24-125 | 5/22/2024 | 6/21/2024 | |
Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01 Clinical Trial Not Allowed) | National Institutes of Health | R01 | RFA-AT-24-008 | 5/28/2024 | 6/28/2024 | |
Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) | National Institutes of Health | transdisciplinary, physician, chemistry, biology, innovation, theory, | PAR-22-147 | 6/1/2024 | 7/1/2024 | |
Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) | National Institutes of Health | Diversity, equity, and inclusion (DEIA), faculty hiring and advancement, institutional climate, surveys, action plans | PAR-24-038 | 6/1/2024 | 7/1/2024 | |
Consortium for Palliative Care Research Across the Lifespan (U54 Clinical Trial Optional) | National Institutes of Health | consortium, palliative care, research, lifespan, serious illness, health disparities | RFA-AG-25-002 | 5/31/2024 | 7/2/2024 | |
Advancing Genomic Medicine Research (R01 Clinical Trial Optional) | National Institutes of Health | innovation, health disparities, genomic information, early-stage, | RFA-HG-23-032 | 7/8/2024 | ||
Advancing Genomic Medicine Research (R21 Clinical Trial Optional) | National Institutes of Health | innovation, health disparities, genomic information, early-stage, | RFA-HG-23-033 | 7/8/2024 | ||
Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) | National Institutes of Health | investigator-initiated research, genomics, health equity | RFA-HG-23-018 | 6/8/2024 | 7/8/2024 | |
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required) | National Institutes of Health | Diversity, Research Scientist Development, Clinical Trial | PAR-21-296 | 7/12/2024 | ||
Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required ) | National Institutes of Health | Early-Stage, Tobacco, postdoctoral, | RFA-OD-22-026 | 5/12/2024 | 7/12/2024 | |
Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | National Institutes of Health | Established, epidemiology, cancer control | PAR-22-162 | 7/29/2024 | ||
Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) | National Institutes of Health | epidemiology, diversity, risks, rural, poverty, population-based research, cohort | PAR-22-161 | 7/29/2024 | ||
Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required) | National Institutes of Health | prevention, health disparities, network, innovation, | PAR-24-053 | 7/5/2024 | 8/5/2024 | |
Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STRR) | National Institutes of Health | quantum sensing, biomedicine, National Institutes of Health (NIH), healthcare, novel imaging systems, early disease detection | R43/R44,R41/R42 | NOT-EY-23-009 | 9/5/2024 | |
(NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes | National Institutes of Health | R01,R03,R21 | NOT-AA-21-028 | 9/7/2024 | ||
(NOSI): Precision Imaging of Oral Lesions | National Institutes of Health | oral lesions, imaging, diagnosis, treatment | R21,R01 | NOT-DE-21-010 | 9/9/2024 | |
(NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions | National Institutes of Health | behavioral interventions, health, development, and testing | R01,R34,R21,UG3/UH3,R61/R33,U54,U01,R21/R33 | NOT-OD-22-203 | 9/26/2024 | |
Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs) (UG3/UH3 Clinical Trial Not Allowed) | National Institutes of Health | Diversity, training, bioengineering, imaging, innovation, education, | RFA-EB-23-006 | 8/31/2024 | 9/30/2024 | |
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | National Institutes of Health | molecular, biomarkers, therapies, clinical | PAR-23-314 | 10/8/2024 | ||
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | National Institutes of Health | molecular, biomarkers, therapies, clinical | PAR-23-313 | 10/8/2024 | ||
Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed) | National Institutes of Health | education, skills development, biomedical, development, predoctoral, postdoctoral | PAR-23-222 | 10/11/2024 | ||
(NOSI): Administrative Supplements for Research on Womens Health in the IDeA States | National Institutes of Health | women's health, IDeA states, health disparities, administrative supplements | Admin Supp | NOT-GM-22-005 | 10/17/2024 | |
Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed) | National Institutes of Health | Gut, Diet, lipids, biochemistry, biology, | PAR-23-051 | 9/23/2024 | 10/23/2024 | |
Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) | National Institutes of Health | Gut, Diet, lipids, biology, early-stage, biochemistry | PAR-23-052 | 9/26/2024 | 10/26/2024 | |
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) | National Institutes of Health | Research Specialist, Laboratory-based Scientist | PAR-23-242 | 10/2/2024 | 11/1/2024 | |
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) | National Institutes of Health | Research Specialist, Core-based Scientist, ESI | PAR-23-243 | 10/2/2024 | 11/1/2024 | |
(NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project | National Institutes of Health | Mentored Career Development INCLUDE Project, Down Syndrome, Research | K99/R00,K23,K08,K01,K43,UE5 | NOT-OD-22-124 | 11/12/2024 | |
(NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed) | National Institutes of Health | health disparities, Asian Americans, Native Hawaiians, Pacific Islanders, National Institutes of Health (NIH), cancer, cardiovascular disease, aging | R21,R01 | NOT-HL-23-001 | 11/18/2024 | |
(NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity | National Institutes of Health | Hunger, Food Insecurity, Nutrition Insecurity, Research | R01,Admin Supp,R21,K01,R34,R33,R61/R33,UG3/UH3,K43 | NOT-OD-22-135 | 11/28/2024 | |
(NOSI): Accelerating Progress in Celiac Disease Research | National Institutes of Health | celiac disease, research, gluten-free diet | R03,R21,U01,U44,R01,R34,P01,R61/R33 | NOT-AI-22-004 | 1/7/2025 | |
(NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities | National Institutes of Health | dental, oral, craniofacial, health disparities, biological factors, | R21,R01 | NOT-DE-21-013 | 1/7/2025 | |
(NOSI): SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) | National Institutes of Health | SBIR, technology transfer, NIH research programs, commercialization, neurological disorders, vision disorders, cancer | R43/R44 | NOT-NS-22-017 | 1/7/2025 | |
(NOSI): Research Council of Finland (RCF) National Institutes of Health (NIH) Partnership Program | National Institutes of Health | collaborative research | R01 | NOT-OD-24-040 | 1/7/2025 | |
Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25 Clinical Trial Not Allowed) | National Institutes of Health | Undergraduate, diversity, bioengineering, STEM, Early-stage | PAR-23-114 | 12/17/2024 | 1/17/2025 | |
Advancing Research Careers (ARC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed) | National Institutes of Health | education, skills development, biomedical, development, predoctoral, postdoctoral | PAR-23-221 | 11/5/2023 | 1/29/2025 | |
NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) | National Institutes of Health | diabetes, kidney diseases, digestive and blood diseases, education programs, training, curriculum development | PAR-24-074 | 1/30/2025 | ||
(NOSI): Administrative Supplements to Prepare Data Assets for Infectious and Immune-mediated Diseases for Inclusion into the NIAID Data Ecosystem | National Institutes of Health | infectious diseases, immune-mediated diseases, data assets, NIAID Data Ecosystem, metadata, FAIR Guiding Principles | Admin Supp | NOT-AI-23-009 | 2/13/2025 | |
NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed) | National Institutes of Health | Biomedical Research, Biomedical Informatics, Scholarly Works, Health Informatics | PAR-23-183 | 1/27/2025 | 2/26/2025 | |
(NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities with a focus on addressing diverse representation in research on Down syndrome (R21 Clinical Trial Optional) | National Institutes of Health | Community-Based, Participatory Research, Health Disparities, Down Syndrome | R21 | NOT-OD-22-142 | 3/16/2025 | |
(NOSI): Developing Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) for Institutions with an emphasis on Down syndrome research (R15 Clinical Trial Not Allowed) | National Institutes of Health | Research Enhancement , Down Syndrome | R15 | NOT-OD-22-136 | 4/10/2025 | |
(NOSI): Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) | National Institutes of Health | Administrative Supplements, Analytical Methods, Dietary Supplement Constituents | Admin Supp | NOT-OD-22-202 | 4/15/2025 | |
(NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project | National Institutes of Health | INCLUDE Project, Down Syndrome, Co-occurring Conditions, Lifespan | R01 | NOT-OD-22-123 | 4/30/2025 | |
(NOSI): Climate Change and Health | National Institutes of Health | climate change, health, NIH Climate Change and Health Initiative | R21,F31,D43,K01,R03,K43,K99/R00,U01,U19,R01,F32,K23,F30,R21/R33 | NOT-ES-22-006 | 5/7/2025 | |
(NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | National Institutes of Health | Evidence-Based Screening, health Disparities, Lifespan | R03,R01,R34,R21,UG3/UH3,R61/R33,Admin Supp | NOT-OD-22-106 | 5/7/2025 | |
(NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan | National Institutes of Health | Health Disparities, Evidence-based, lifespan | R21,R01,UG3/UH3,R61/R33,R34,R03 | NOT-OD-22-178 | 5/7/2025 | |
Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Research (BSSR) - Institutional Research Training Program [T32] | National Institutes of Health | Predoctoral Training, Advanced Data Analytics, Behavioral and Social Sciences Research (BSSR), Institutional Research Training Program, T32 | RFA-OD-24-012 | 5/24/2025 | ||
(NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project | National Institutes of Health | Administrative Supplements, INCLUDE Project, Down Syndrome | Admin Supp, | NOT-OD-22-137 | 6/1/2025 | |
(NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery | National Institutes of Health | pain research, pain measurement, non-addictive pain medications, chronic pain | R61/R33 | NOT-NS-22-095 | 6/24/2025 | |
(NOSI): Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes | National Institutes of Health | minor cannabinoids, terpenes, cannabis, therapeutic benefits, pain, analgesia, inflammation, cancer, glaucoma, neurological disorders, | R21,R01,UG3/UH3 | NOT-AT-22-027 | 6/30/2025 | |
(NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations | National Institutes of Health | sexual and gender minority (SGM) health, social determinants of health, mental health, cancer | R01,K08,K99/R00,K01,K23,R21,K25,K18,R03,P50,F99/K00,UG3/UH3,R34,R25,U01 | NOT-MD-22-012 | 8/7/2025 | |
(NOSI): Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars | National Institutes of Health | Administrative Supplements, Research Continuity, Retention, Mentored Career Development, K Award Recipients, Scholars | Admin Supp | NOT-OD-23-031 | 9/30/2025 | |
(NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards | National Institutes of Health | Administrative Supplement, Biomedical, Behavioral Research, First-Time Recipients, Research Project Grant Awards | Admin Supp | NOT-OD-23-032 | 9/30/2025 | |
(NOSI): Health Influences of Gender as a Social and Structural Variable | National Institutes of Health | Gender, Social Variable, Structural Variable, Health Influences | K08,R01,K23,R21,K01,R03,F31,R34 | NOT-OD-24-038 | 9/30/2025 | |
(NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities | National Institutes of Health | Preventive Interventions, Cardiometabolic Risk Factors, Health Disparities | R01,R21,R34,R03,UG3/UH3 | NOT-OD-22-154 | 10/5/2025 | |
BRAIN Initiative: Production and distribution facilities for brain cell type-specific access reagents (U24 Clinical Trial Not Allowed) | National Institutes of Health | brain cell type-specific access reagents, brain circuit function, dissection of neural circuits, scalable production and distribution facilities, cell type-selective access reagents, BRAIN Initiative Armamentarium project | RFA-MH-25-105 | 10/1/2025 | 10/31/2025 | |
(NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics | National Institutes of Health | R01,R41/R42,R43/R44,R21 | NOT-AI-23-001 | 1/7/2026 | ||
(NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases | National Institutes of Health | endocannabinoid system, ECS, cannabinoids, substance use, substance use disorder, SUD, physiological processes, analgesia, anti-inflammatory, nervous system | R01,R21,DP2,DP1,K99/R00,K01,R36,K08,R15,K24 | NOT-DA-22-048 | 1/7/2026 | |
(NOSI): Research on Family Support and Rejection in the Health and Well-Being of SGM Populations | National Institutes of Health | sexual and gender minority (SGM), family support, family rejection, health, well-being, research, LGBTQI2S+, impact, consequences | R21,R15,R01,R34,K25,K99/R00,K01,R03,P01,K08,K23 | NOT-OD-23-166 | 5/7/2026 | |
(NOSI): Synthetic Biology for Biomedical Applications. | National Institutes of Health | synthetic biology, biomedical applications | R01,R21,R35,R41/R42,R43/R44 | NOT-EB-23-002 | 5/16/2026 | |
(NOSI): Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations | National Institutes of Health | immigrant health, health disparities, health advantages, social determinants of health, acculturation, biological factors, immigration policies, local contexts | R01,R61/R33 | NOT-MD-23-002 | 6/5/2026 | |
(NOSI): Addressing Health Disparities Among Immigrant Populations Through Effective Interventions | National Institutes of Health | immigrant health, health disparities, interventions, social determinants of health, immigration process | R01 | NOT-MD-23-003 | 6/5/2026 | |
(NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities | National Institutes of Health | vaccine hesitancy, vaccine uptake, vaccine implementation, health disparities, | R01,R21 | NOT-MD-23-008 | 6/5/2026 | |
(NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research | National Institutes of Health | NOT-AT-24-034 | 9/3/2026 | |||
(NOSI): Epidemiology and Prevention in Alcohol Research | National Institutes of Health | alcohol, epidemiology, prevention, research | R03,R21,R01,UG3/UH3,R61/R33 | NOT-AA-23-018 | 9/5/2026 | |
(NOSI): Research Supplements to Promote Re-Entry, Re-integration into, and Re-training in Health-Related Research Careers (Admin Supp - Clinical Trial Not Allowed) | National Institutes of Health | Research Supplements, Re-entry, Re-integration, Re-training, Health-Related Research Careers, Clinical Trial Not Allowed | Admin Supp | NOT-OD-23-170 | 10/8/2026 | |
(NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities | National Institutes of Health | telehealth, rural communities, healthcare access, provider-to-provider telehealth (PPT), real-world effectiveness, implementation | R01,R21 | NOT-HL-23-083 | 10/9/2026 | |
(NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) | National Institutes of Health | RNA-based therapeutics, delivery, non-viral, small business, pre-clinical | R43/R44,R41/R42 | NOT-AI-24-007 | 1/5/2027 | |
(NOSI): Data Informed, Place-Based Community-Engaged Research to Advance Health Equity | National Institutes of Health | geospatial data, health disparities, place-based research, social determinants of health, community-engaged research | R01,R34,R21,UG3/UH3,K01,R03,P01,P50,K08,K23 | NOT-HL-23-110 | 1/7/2027 | |
(NOSI): Quantum Sensing Technologies in Biomedical Applications | National Institutes of Health | quantum sensing, biomedical applications, quantum technologies | R35,RM1,R21,R01,U01,R15,R13,K99/R00 | NOT-EB-23-022 | 1/26/2027 |
Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.